STEMCELL Technologies Wins Support from Western Innovation (WINN) Initiative
News Sep 27, 2014
STEMCELL Technologies has received $949,500 in repayable assistance from the Western Innovation (WINN) Initiative for an exciting project to develop tools and assays for three-dimensional (3D) cell culture.
Led by Dr. Steven Woodside, Director of Particle Chemistry and Engineering, and Dr. Eric Jervis, Principal Scientist, the project builds on STEMCELL Technologies’ extensive experience in developing culture systems and specialized cell culture media for life science research.
3D cell culture better mirrors the environment experienced by cells in the body, and so provides improved physiological relevance for many areas of research and drug development, including cancer research, cell therapy, drug screening, toxicity testing and tissue/organ engineering.
The development of convenient and robust 3D culture systems is critical to these important fields. Studies based on 3D culture are more predictive of disease states and drug responses, and enable more mechanistically accurate modelling of the target tissue.
Commenting on the award, Dr. Allen Eaves, CEO and President of STEMCELL Technologies stated: “We are thrilled to have received the support of the Western Innovation Initiative and are confident the project will accelerate life science research and facilitate the development of novel drug formulations.”
Chemicals in Lavender and Tea Tree Oil Could be Hormone DisruptorsNews
A new study lends further evidence to a suspected link between abnormal breast growth in young boys--called prepubertal gynecomastia--and regular exposure to lavender or tea tree oil, by finding that key chemicals in these common plant-derived oils act as endocrine-disrupting chemicals.READ MORE
Mending Broken Hearts with Cardiomyocyte MoldsNews
A team of researchers at Michigan Technological University in collaboration with Harvard Medical School, shows how cardiomyocytes grown in a heart-like environment mature more quickly, have improved functionality and are less likely to be rejected by patients’ bodies.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE